Summary
Parkinson's disease is often driven by a malfunctioning protein called LRRK2. This protein acts like a biological switch known as a kinase. In many patients, genetic mutations cause LRRK2 to become overactive, which eventually leads to the death of brain cells. Even in patients without these specific mutations, an overactive LRRK2 protein seems to be a major culprit behind the disease. Until now, scientists have not fully understood exactly how this protein gets locked into its destructive state.
Recent laboratory research has uncovered a microscopic battle between LRRK2 and another protein called PP2A. Proteins often control each other by adding or removing chemical tags called phosphates. The researchers found that PP2A acts like a cellular brake. It removes phosphates from LRRK2, which breaks the LRRK2 proteins apart and calms their hyperactive behavior. However, LRRK2 fights back. It places a phosphate tag directly onto a critical part of PP2A, shutting down the brake by preventing it from assembling properly.
This vicious cycle has real consequences for brain cells. When researchers introduced healthy, fully functional PP2A into cellular models of Parkinson's disease, it protected the neurons from dying. But when they used a mutated version of PP2A that had been sabotaged by LRRK2, the protective effect vanished. While these results are promising, scientists note that the findings are early-stage. The experiments were conducted in test tubes and lab-grown cells, meaning future studies in living organisms are required to confirm if this same battle happens in the human brain.
Why it matters.
Parkinson's disease affects millions of people worldwide, and current treatments primarily manage symptoms rather than halting the underlying brain degeneration. Because LRRK2 is known to be one of the most common genetic culprits behind Parkinson's, the pharmaceutical industry has heavily invested in creating drugs to block its activity. Understanding exactly how LRRK2 is naturally regulated by PP2A gives drug developers a completely new pathway to explore. Instead of only trying to block LRRK2 directly, future medicines might focus on boosting the protective power of PP2A or preventing LRRK2 from sabotaging it.
If researchers can successfully target this mechanism, it could lead to therapies that physically protect neurons from dying. Furthermore, since overactive LRRK2 is involved in both inherited and non-inherited forms of Parkinson's disease, drugs inspired by this newly discovered biological loop could potentially help a vast majority of the patient population.
The story in numbers.
- Critical PPP2CA residue phosphorylated by LRRK2
- T304
- LRRK2 mutation evaluated for induced neuronal cell death
- G2019S
Follow the evidence.
This source is a preprint and has not completed peer review. Its findings are provisional.